The insulin-like growth factor-1 receptor (IGF-1R) is a central component of lung cancer signal transduction pathways. A phase III study failed for carboplatin, paclitaxel, with or without figitumumab in first-line treating metastatic non-small cell lung cancer (NSCLC).

Signalling through the IGF-1R is the principal pathway responsible for somatic growth in fetal mammals, while somatic growth in postnatal animals is achieved through the synergistic interaction of growth hormone (GH) and the IGFs.

2019年10月8日 · Type 1 insulin-like growth factor receptor (IGF1R) is a receptor tyrosine kinase that regulates cell growth and proliferation, and can be activated by IGF1, IGF2, and insulin. Here,...

2024年12月25日 · IGF1R (Insulin Like Growth Factor 1 Receptor) is a Protein Coding gene. Diseases associated with IGF1R include Insulin-Like Growth Factor I and Growth Delay Due To Insulin-Like Growth Factor I Resistance. Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway.

2003年11月6日 · The vascular insulin-like growth factor (IGF)-1 system includes the IGFs, the IGF-1 receptor (IGF-1R), and multiple binding proteins. This growth factor system exerts multiple physiologic effects on the vasculature through both endocrine and …

IGF1R stimulates autophagy, enhances viability, and promotes insulin secretion in pancreatic beta cells in gestational diabetes mellitus by upregulating ATG7. Exosomal miR-223 promotes ARDS by targeting insulin-like growth factor 1 receptor: A cell communication study.

1 天前 · SYCUME ® (teprotumumab N01) is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody developed by Innovent for the treatment of TED. IGF-1R is a transmembrane tyrosine kinase receptor involved in development, metabolism, and immune regulation, and is overexpressed in OFs, B cells, and T cells of TED patients [10].

1 天前 · Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody for thyroid eye disease (TED). The National Medical Products Administration (NMPA) cleared the treatment, making it the second IGF-1R antibody therapy approved globally.

1 天前 · When GH is secreted by the anterior pituitary, it binds to receptors on liver cells, triggering IGF-1 synthesis and release into circulation. IGF-1 then interacts with its receptor (IGF-1R) on target tissues, activating signaling pathways that …

2023年1月1日 · Here we review the occurrence of IGF-1R aberrations and activation mechanisms in cancers, which justify the development of anti-IGF-1R therapies. We describe the therapeutic agents available for IGF-1R inhibition, with focuses on …